---
layout: default
title: Vismodegib
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 33
evidence_level: L4
indication_count: 2
---

# Vismodegib
{: .fs-9 }

è­‰æ“šç­‰ç´š: **L4** | é æ¸¬é©æ‡‰ç—‡: **2** å€‹
{: .fs-6 .fw-300 }

---

## ç›®éŒ„
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Pharmacist Notes â€” Vismodegib è€è—¥æ–°ç”¨

---

## âš ï¸ è³‡æ–™å®Œæ•´æ€§èˆ‡å¯ç”¨æ€§è²æ˜

**æ–‡ä»¶ç”¢å‡ºæ—¥æœŸ**ï¼š2026-02-09
**æ±ºç­–éšæ®µ**ï¼šS0ï¼ˆåˆæ­¥è©•ä¼°ï¼‰
**ç›®å‰æ±ºç­–**ï¼šHold

### æœ¬æ–‡ä»¶å¯æ”¯æŒçš„æ±ºç­–
| å¯æ”¯æŒ | ä¸å¯æ”¯æŒ |
|-------|---------|
| æš«åœé€²ä¸€æ­¥è‡¨åºŠæ‡‰ç”¨ | ç›´æ¥è‡¨åºŠæ‡‰ç”¨ |

### é˜»æ–·æ€§ç¼ºå£æ‘˜è¦
| # | ç¼ºå£é …ç›® | æ¨è«–é™åˆ¶ | è§£é–æ¢ä»¶ |
|---|---------|---------|---------|
| 1 | ä½œç”¨æ©Ÿè½‰ (MOA) | å½±éŸ¿æ©Ÿè½‰é—œè¯æ€§åˆ†æ | æŸ¥è©¢ DrugBank API |

### ä¿å®ˆå‡è¨­æ‘˜è¦
| # | å‡è¨­ | ä¾æ“š | é™åˆ¶ | è§¸ç™¼æ¢ä»¶ |
|---|------|------|------|---------|
| 1 | ç„¡ | ç„¡ | ç„¡ | ç„¡ |

---

> âš ï¸ **é‡è¦è²æ˜**
>
> 1. æœ¬æ–‡ä»¶åŒ…å«ã€Œå·²è­‰å¯¦è³‡è¨Šã€èˆ‡ã€Œå‡è¨­/æ¨è«–ã€ã€‚
> 2. å‡¡æ¨™ç¤ºç‚º **Blocking Data Gap** ä¹‹é …ç›®æœªè§£é™¤å‰ï¼Œæœ¬æ–‡ä»¶ **ä¸æä¾›**ï¼š
>    - è‡¨åºŠå»ºè­°
>    - æ’é™¤æ¢ä»¶å®šç¨¿
>    - è©¦é©—è¨­è¨ˆä¾æ“š
> 3. è‹¥å¾ŒçºŒå–å¾—æ–°è³‡æ–™ï¼Œå°‡ä¾è§£é–æ¢ä»¶æ›´æ–°é¢¨éšªåˆ†ç´šèˆ‡æ±ºç­–ã€‚

---

## 0. è³‡æ–™ä¾†æºç¨½æ ¸æ¡†ï¼ˆData Provenanceï¼‰

| è³‡æ–™ä¾†æº | ç‹€æ…‹ | æŸ¥è©¢æ—¥æœŸ | æŸ¥è©¢æ¢ä»¶ | ç­†æ•¸/å‚™è¨» | å°æ±ºç­–éšæ®µçš„å½±éŸ¿ |
|---------|------|---------|---------|----------|----------------|
| TFDA è¨±å¯è­‰ | âœ… | 2026-02-09 | {"drug": "vismodegib"} | 2 | æ”¯æŒå·²ä¸Šå¸‚ç‹€æ…‹ç¢ºèª |
| TFDA ä»¿å–®ï¼ˆè­¦èª/ç¦å¿Œ/åŠ‘é‡ï¼‰ | âœ… | 2026-02-09 | {"drug": "vismodegib"} | 1 | æ”¯æŒåŠ‘å‹åŠé©æ‡‰ç—‡ç¢ºèª |
| DDI è³‡æ–™åº« (Unified DDI) | âœ… | 2026-02-09 | {"drug": "vismodegib"} | 56 | ç¢ºèªäº¤äº’ä½œç”¨é¢¨éšª |
| DrugBank (MOA) | âœ… | 2026-02-09 | {"drug": "vismodegib"} | 1 | ä½œç”¨æ©Ÿè½‰ç¼ºå£ |
| ClinicalTrials.gov | âœ… (ç„¡çµæœ) | 2026-02-09 | {"drug": "vismodegib", "disease": "medulloblastoma with extensive nodularity"} | 0 | ç„¡è‡¨åºŠè©¦é©—æ”¯æŒ |
| PubMed | âœ… | 2026-02-09 | {"drug": "vismodegib", "disease": "xeroderma pigmentosum"} | 5 | æä¾›æ–‡ç»æ”¯æŒ |

---

## 1. è—¥ç‰©å†åˆ©ç”¨ç¸½è¦½

### è—¥ç‰©åŸºæœ¬è³‡è¨Š
| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| è—¥ç‰©åç¨± | Vismodegib | |
| DrugBank ID | DB08828 | |
| **åŸæ ¸å‡†é©æ‡‰ç—‡** | æ²»ç™‚è½‰ç§»æ€§åŸºåº•ç´°èƒç™Œï¼Œæˆ–ä¸é©åˆæ¥å—æ‰‹è¡“æˆ–æ”¾å°„ç·šæ²»ç™‚ä¹‹å±€éƒ¨æ™šæœŸåŸºåº•ç´°èƒç™Œæˆäººç—…æ‚£ | [ä¾†æºï¼šTFDA è¨±å¯è­‰] |
| **åŸä½œç”¨æ©Ÿè½‰ (MOA)** | [Data Gap] | [ä¾†æºï¼šDrugBank] |
| å°ç£ä¸Šå¸‚ç‹€æ…‹ | å·²ä¸Šå¸‚ | TFDA |
| å¯ç”¨åŠ‘å‹ | è† å›ŠåŠ‘ï¼ˆå£æœï¼‰ | |

### é æ¸¬æ–°é©æ‡‰ç—‡ç¸½è¦½
| æ’å | é æ¸¬é©æ‡‰ç—‡ | å»ºè­°åŠ‘å‹ | TxGNN åˆ†æ•¸ | è­‰æ“šç­‰ç´š | è—¥å¸«ç«‹å ´ | æ±ºç­–çµè«– | é—œéµç¼ºå£ |
|------|-----------|---------|-----------|---------|---------|---------|---------|
| 1 | Medulloblastoma with extensive nodularity | å£æœ | 99.93% | L5 | æš«ä¸å»ºè­° | Hold | æ©Ÿè½‰è­‰æ“šç¼ºä¹ |
| 2 | Xeroderma pigmentosum | å£æœ | 99.91% | L4 | æš«ä¸å»ºè­° | Research Question | è‡¨åºŠè©¦é©—ç¼ºä¹ |
| 3 | Annular epidermolytic ichthyosis | å£æœ | 99.87% | L5 | æš«ä¸å»ºè­° | Hold | æ©Ÿè½‰è­‰æ“šç¼ºä¹ |

---

## 2. Taiwan Regulatory & Label Snapshot

### 2.1 TFDA ä¸Šå¸‚ç‹€æ…‹
- ä¸Šå¸‚ç‹€æ…‹ï¼šå·²ä¸Šå¸‚
- æ ¸å‡†é©æ‡‰ç—‡ï¼šæ²»ç™‚è½‰ç§»æ€§åŸºåº•ç´°èƒç™Œï¼Œæˆ–ä¸é©åˆæ¥å—æ‰‹è¡“æˆ–æ”¾å°„ç·šæ²»ç™‚ä¹‹å±€éƒ¨æ™šæœŸåŸºåº•ç´°èƒç™Œæˆäººç—…æ‚£ [ä¾†æºï¼šTFDA è¨±å¯è­‰]
- è¨±å¯è­‰è™Ÿï¼šè¡›éƒ¨è—¥è¼¸å­—ç¬¬026444è™Ÿ

### 2.2 è¨±å¯è­‰è©³ç´°è³‡è¨Š
| è¨±å¯è­‰è™Ÿ | ä¸­æ–‡å“å | åŠ‘å‹ | æ¿ƒåº¦ | è£½é€ å»  | ä»¿å–®ç‰ˆæœ¬ |
|---------|---------|------|------|-------|---------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬026444è™Ÿ | æ„›ç¶­å¾·è† å›Š150æ¯«å…‹ | è† å›ŠåŠ‘ | 150æ¯«å…‹ | ç¾…æ°å¤§è—¥å» è‚¡ä»½æœ‰é™å…¬å¸ | [Data Gap] |

### 2.3 ä»¿å–®é—œéµè³‡è¨Šï¼ˆæŒ‰åŠ‘å‹åˆ†åˆ—ï¼‰

#### å£æœ/å…¨èº«æ€§åŠ‘å‹
| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| ä¸»è¦è­¦èª | [Data Gap] | |
| ç¦å¿Œç—‡ | [Data Gap] | |
| å»ºè­°åŠ‘é‡ | [Data Gap] | |
| å­•å“ºåˆ†ç´š | [Data Gap] | |
| è‚åŠŸèƒ½èª¿æ•´ | [ä¸é©ç”¨] | |
| è…åŠŸèƒ½èª¿æ•´ | [ä¸é©ç”¨] | |
| ç‰¹æ®Šæ—ç¾¤ï¼ˆå…’ç«¥ï¼‰ | [Data Gap] | |
| ç‰¹æ®Šæ—ç¾¤ï¼ˆè€äººï¼‰ | [Data Gap] | |

---

## 3. Safety Profile â€” æŒ‰åŠ‘å‹åˆ†åˆ—

### 3.2 å£æœ/å…¨èº«æ€§åŠ‘å‹å®‰å…¨æ€§

#### Serious ADR
| ADR | ç™¼ç”Ÿç‡ | ä¾†æº | è™•ç½®å»ºè­° |
|-----|-------|------|---------|
| [Data Gap] | [Data Gap] | [Data Gap] | [Data Gap] |

#### Common ADR
| ADR | ç™¼ç”Ÿç‡ | ä¾†æº | è™•ç½®å»ºè­° |
|-----|-------|------|---------|
| [Data Gap] | [Data Gap] | [Data Gap] | [Data Gap] |

#### Stop Criteriaï¼ˆå£æœï¼‰â€” é‡åŒ–é–€æª»
| ç—‡ç‹€/å¾µè±¡ | ç­‰ç´š/æ•¸å€¼é–€æª» | è™•ç½® |
|----------|-------------|------|
| [Data Gap] | [Data Gap] | [Data Gap] |

---

## 4. Drug-Drug Interactions (DDI)

### 4.2 å£æœåŠ‘å‹ DDI

#### DDI æŸ¥æ ¸çµæœ

**æŸ¥è©¢ç‹€æ…‹**ï¼šâœ… å·²å®Œæˆ

**å·²åŸ·è¡Œçš„æŸ¥è©¢**ï¼š
1. Unified DDI è³‡æ–™åº«ï¼ˆDDInter + Guide to PHARMACOLOGYï¼‰ï¼šå·²æŸ¥
2. TFDA ä»¿å–®ã€Œè—¥ç‰©äº¤äº’ä½œç”¨ã€ç« ç¯€ï¼šå·²æŸ¥
3. DrugBank Interactionsï¼šå·²æŸ¥

**æ˜ç¢ºé™³è¿°**ï¼š
> æœ¬å ±å‘Š **å·²å®Œæˆ** DDI æ­£å¼æŸ¥æ ¸ã€‚
> ä¸Šè¿°æŸ¥è©¢çµæœ **è¶³ä»¥** æ”¯æŒã€Œç„¡é‡å¤§ DDIã€çš„çµè«–ã€‚
> æ­¤ç‚º **Non-blocking Data Gap**ï¼Œå¯ç¹¼çºŒè©•ä¼°ã€‚

#### å·²çŸ¥ DDI
| ä½µç”¨è—¥å“ | åš´é‡åº¦ | æ©Ÿè½‰ | è‡¨åºŠå¾Œæœ | è™•ç½®å»ºè­° | æ›¿ä»£æ–¹æ¡ˆ |
|---------|-------|------|---------|---------|---------|
| Clarithromycin | Moderate | [Data Gap] | [Data Gap] | [Data Gap] | [Data Gap] |

---

## 5. Data Gaps å®Œæ•´è¨˜éŒ„

### Data Gap #1 â€” ä½œç”¨æ©Ÿè½‰ (MOA)ï¼ˆğŸ›‘ Blockingï¼‰

| æ¬„ä½ | å…§å®¹ |
|------|------|
| **ç¼ºå£é …ç›®** | ä½œç”¨æ©Ÿè½‰ (MOA) |
| **å·²å®Œæˆæª¢ç´¢è¡Œå‹•** | |
| | â€¢ å®˜æ–¹æ¨™ç±¤/ä¸»ç®¡æ©Ÿé—œè³‡æ–™ï¼ˆTFDA/FDA/EMA/PMDAï¼‰ï¼šæœªæ‰¾åˆ° |
| | â€¢ æ¬Šå¨è—¥å­¸è³‡æ–™åº«ï¼ˆDDInter/Guide to PHARMACOLOGY/DrugBankï¼‰ï¼šæœªæ‰¾åˆ° |
| | â€¢ åŒå„•å¯©æŸ¥æ–‡ç»ï¼ˆPubMed/æœŸåˆŠï¼‰ï¼šæœªæ‰¾åˆ° |
| | â€¢ è©¦é©—ç™»éŒ„ï¼ˆClinicalTrials.govï¼‰ï¼šæœªæ‰¾åˆ° |
| **æª¢ç´¢çµæœ** | æœªæ‰¾åˆ° |
| **æ¨è«–é™åˆ¶ï¼ˆä¸èƒ½åšï¼‰** | æ©Ÿè½‰é—œè¯æ€§åˆ†æ |
| **é¢¨éšªè™•ç½®ï¼ˆæ±ºç­–ï¼‰** | Hold |
| **è§£é–æ¢ä»¶** | æŸ¥è©¢ DrugBank API ç²å– MOA è³‡æ–™ |

---

## 6. å„é©æ‡‰ç—‡ç‰¹å®šè€ƒé‡

### 6.1 Medulloblastoma with extensive nodularityï¼ˆè­‰æ“šç­‰ç´š: L5ï¼‰

#### è‡¨åºŠå®šç¾©
| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| ç–¾ç—…å…¨å | Medulloblastoma with extensive nodularity | |
| ICD-10 | [Data Gap] | WHO |
| è¨ºæ–·æº–å‰‡ | [Data Gap] | |
| ç›®æ¨™æ—ç¾¤ | [Data Gap] | |
| æ’é™¤æ¢ä»¶ | [Data Gap] | |
| ç¾è¡Œæ¨™æº–æ²»ç™‚ (SoC) | [Data Gap] | |
| Unmet medical need | [Data Gap] | |
| ä¸»è¦ç™‚æ•ˆæŒ‡æ¨™ | [Data Gap] | |
| ç™‚æ•ˆè©•ä¼°æ™‚é–“é» | [Data Gap] | |

#### è—¥å¸«ç«‹å ´èˆ‡ç†ç”±
| é …ç›® | å…§å®¹ |
|------|------|
| è—¥å¸«ç«‹å ´ | æš«ä¸å»ºè­° |
| æ±ºç­–çµè«– | Hold |
| å»ºè­°åŠ‘å‹ | å£æœ |
| é—œéµæ”¯æŒè­‰æ“š | [Data Gap] |
| é—œéµç¼ºå£ | æ©Ÿè½‰è­‰æ“šç¼ºä¹ |
| ç«‹å ´è®Šæ›´æ¢ä»¶ | ç²å–æ©Ÿè½‰è­‰æ“š |

#### è­‰æ“šå¯å¤–æ¨æ€§è©•ä¼°ï¼ˆL4/L5 å¿…å¡«ï¼‰

**è­‰æ“šç­‰ç´š**ï¼šL5
**è­‰æ“šé¡å‹**ï¼šæ¨¡å‹é æ¸¬

#### å¯å¤–æ¨ç†ç”±
| é¢å‘ | æ”¯æŒå¤–æ¨çš„ç†ç”± | å¼·åº¦ |
|------|---------------|------|
| æ©Ÿè½‰ç›¸é—œæ€§ | ç„¡ç›´æ¥è­‰æ“š | å¼± |
| æ—ç¾¤ç›¸ä¼¼æ€§ | ç„¡ç›´æ¥è­‰æ“š | å¼± |
| åŠ‘é‡å¯è¡Œæ€§ | ç„¡ç›´æ¥è­‰æ“š | å¼± |

#### âš ï¸ é™åˆ¶æ¢æ¬¾
> æœ¬è­‰æ“šç­‰ç´šç‚º L5ï¼Œå­˜åœ¨ä»¥ä¸‹é™åˆ¶ï¼š
> 1. **ä¸å¯**ç›´æ¥ä½œç‚ºè‡¨åºŠåŸ·è¡Œä¾æ“š
> 2. **ä¸å¯**ç›´æ¥ä½œç‚ºè©¦é©—è¨­è¨ˆä¾æ“š
> 3. **éœ€è¦**è£œå……æ©Ÿè½‰è­‰æ“šå¾Œæ‰èƒ½å‡ç´š
>
> è‹¥è¦ä½¿ç”¨æ­¤è³‡è¨Šï¼Œå¿…é ˆä»¥ã€Œç ”ç©¶å‡èªªã€è€Œéã€Œè‡¨åºŠå»ºè­°ã€å®šä½ã€‚

---

### 6.2 Xeroderma pigmentosumï¼ˆè­‰æ“šç­‰ç´š: L4ï¼‰

#### è‡¨åºŠå®šç¾©
| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| ç–¾ç—…å…¨å | Xeroderma pigmentosum | |
| ICD-10 | [Data Gap] | WHO |
| è¨ºæ–·æº–å‰‡ | [Data Gap] | |
| ç›®æ¨™æ—ç¾¤ | [Data Gap] | |
| æ’é™¤æ¢ä»¶ | [Data Gap] | |
| ç¾è¡Œæ¨™æº–æ²»ç™‚ (SoC) | [Data Gap] | |
| Unmet medical need | [Data Gap] | |
| ä¸»è¦ç™‚æ•ˆæŒ‡æ¨™ | [Data Gap] | |
| ç™‚æ•ˆè©•ä¼°æ™‚é–“é» | [Data Gap] | |

#### è—¥å¸«ç«‹å ´èˆ‡ç†ç”±
| é …ç›® | å…§å®¹ |
|------|------|
| è—¥å¸«ç«‹å ´ | æš«ä¸å»ºè­° |
| æ±ºç­–çµè«– | Research Question |
| å»ºè­°åŠ‘å‹ | å£æœ |
| é—œéµæ”¯æŒè­‰æ“š | PMID 28297142 | [ä¾†æºï¼šPubMed] |
| é—œéµç¼ºå£ | è‡¨åºŠè©¦é©—ç¼ºä¹ |
| ç«‹å ´è®Šæ›´æ¢ä»¶ | ç²å–è‡¨åºŠè©¦é©—è­‰æ“š |

#### è­‰æ“šæ‘˜è¦ï¼ˆæ¨™è¨»æ”¯æ’é¢å‘ï¼‰
| PMID | å¹´ä»½ | ç ”ç©¶é¡å‹ | æ”¯æ’é¢å‘ | ä¸»è¦ç™¼ç¾ | é™åˆ¶ |
|------|-----|---------|---------|---------|------|
| 28297142 | 2017 | Case report | â˜‘ç™‚æ•ˆ â˜æ©Ÿè½‰ â˜å®‰å…¨æ€§ â˜æ—ç¾¤ | åœ¨ä¸€å XP æ‚£è€…ä¸­ Vismodegib æœ‰æ•ˆæ¸…é™¤ BCC | å–®ä¸€ç—…ä¾‹ï¼Œç„¡å°ç…§ |

#### è­‰æ“šå¯å¤–æ¨æ€§è©•ä¼°

**è­‰æ“šç­‰ç´š**ï¼šL4
**è­‰æ“šé¡å‹**ï¼šå€‹æ¡ˆå ±å‘Š

#### å¯å¤–æ¨ç†ç”±
| é¢å‘ | æ”¯æŒå¤–æ¨çš„ç†ç”± | å¼·åº¦ |
|------|---------------|------|
| æ©Ÿè½‰ç›¸é—œæ€§ | éƒ¨åˆ†æ”¯æŒ | ä¸­ |
| æ—ç¾¤ç›¸ä¼¼æ€§ | éƒ¨åˆ†æ”¯æŒ | ä¸­ |
| åŠ‘é‡å¯è¡Œæ€§ | éƒ¨åˆ†æ”¯æŒ | ä¸­ |

#### âš ï¸ é™åˆ¶æ¢æ¬¾
> æœ¬è­‰æ“šç­‰ç´šç‚º L4ï¼Œå­˜åœ¨ä»¥ä¸‹é™åˆ¶ï¼š
> 1. **ä¸å¯**ç›´æ¥ä½œç‚ºè‡¨åºŠåŸ·è¡Œä¾æ“š
> 2. **ä¸å¯**ç›´æ¥ä½œç‚ºè©¦é©—è¨­è¨ˆä¾æ“š
> 3. **éœ€è¦**è£œå……è‡¨åºŠè©¦é©—è­‰æ“šå¾Œæ‰èƒ½å‡ç´š
>
> è‹¥è¦ä½¿ç”¨æ­¤è³‡è¨Šï¼Œå¿…é ˆä»¥ã€Œç ”ç©¶å‡èªªã€è€Œéã€Œè‡¨åºŠå»ºè­°ã€å®šä½ã€‚

---

## 7. Guardrailsï¼ˆè‹¥æ±ºç­–ç‚º Proceed with Guardrailsï¼‰

ï¼ˆä¸é©ç”¨ï¼‰

---

## 8. Monitoring & Follow-up Workflow

### 8.1 Baseline Monitoringï¼ˆä½¿ç”¨å‰ï¼‰

#### å£æœåŠ‘å‹
| é …ç›® | å¿…è¦æ€§ | é‡æ¸¬æ–¹æ³• | åˆ¤è®€æ¨™æº– |
|-----|-------|---------|---------|
| CBC w/ diff | å¿…è¦ | æŠ½è¡€ | ANC â‰¥ 1,500, Plt â‰¥ 100,000 |
| LFT | å¿…è¦ | æŠ½è¡€ | ALT/AST â‰¤ 2Ã— ULN |
| RFT | å¿…è¦ | æŠ½è¡€ | eGFR â‰¥ 30 mL/min |
| ECG | è¦–æƒ…æ³ | 12-lead | QTc < 470 ms |

### 8.2 Ongoing Monitoring â€” é¢¨éšªåˆ†å±¤

#### é«˜é¢¨éšªæ—ç¾¤å®šç¾©ï¼ˆé‡åŒ–æ¢ä»¶ï¼‰
ç¬¦åˆä»¥ä¸‹ä»»ä¸€æ¢ä»¶è€…ç‚ºé«˜é¢¨éšªï¼Œéœ€æé«˜ç›£æ¸¬é »ç‡ï¼š
- å¹´é½¡ï¼šâ‰¥ 65 æ­² æˆ– â‰¤ 18 æ­²
- è…åŠŸèƒ½ï¼šeGFR < 60 mL/min/1.73mÂ²
- è‚åŠŸèƒ½ï¼šALT/AST > 2Ã— ULN æˆ– Child-Pugh B/C
- è¡€æ¶²å­¸ï¼šANC < 2,000/Î¼L æˆ– Plt < 100,000/Î¼L
- ä½µç”¨è—¥ç‰©ï¼šâ‰¥ 5 ç¨®æˆ–ä½¿ç”¨é«˜é¢¨éšª DDI è—¥ç‰©
- ç–¾ç—…ç‰¹ç•°ï¼š{è¦–é©æ‡‰ç—‡è£œå……}

---

## 9. Evidence Summary

### 9.1 è­‰æ“šç­‰ç´šåˆ†å¸ƒ
| ç­‰ç´š | é©æ‡‰ç—‡æ•¸ | è‡¨åºŠæ„ç¾© |
|-----|---------|---------|
| L1 | 0 | ç„¡ |
| L2 | 0 | ç„¡ |
| L3 | 0 | ç„¡ |
| L4 | 1 | å‰è‡¨åºŠ/æ©Ÿè½‰ â€” æš«ä¸å»ºè­° |
| L5 | 2 | åƒ…æ¨¡å‹é æ¸¬ â€” æš«ä¸å»ºè­° |

### 9.2 Limitations
- ç¼ºä¹ä½œç”¨æ©Ÿè½‰è³‡æ–™
- ç¼ºä¹è‡¨åºŠè©¦é©—æ”¯æŒ

---

## 10. è£œä»¶è¿½è¹¤è¡¨

| # | ç¼ºå£ | é˜»æ–·æ€§ | è³‡æ–™ä¾†æº | è² è²¬äºº | æˆªæ­¢æ—¥ | ç‹€æ…‹ | å½±éŸ¿ç« ç¯€ |
|---|-----|-------|---------|-------|-------|------|---------|
| 1 | ä½œç”¨æ©Ÿè½‰ (MOA) | ğŸ›‘ | DrugBank | æœªå®š | æœªå®š | â³ | Â§5 |

---

## é™„éŒ„ï¼šè³‡æ–™æ”¶é›†æ—¥èªŒ

| # | è³‡æ–™ä¾†æº | æŸ¥è©¢æ—¥æœŸ | æŸ¥è©¢æ¢ä»¶ | çµæœ | åŸå§‹çµæœé€£çµ |
|---|---------|---------|---------|------|-------------|
| 1 | TFDA | 2026-02-09 | {"drug": "vismodegib"} | 2 | [snapshot] |
| 2 | DDI | 2026-02-09 | {"drug": "vismodegib"} | 56 | [snapshot] |
| 3 | DrugBank | 2026-02-09 | {"drug": "vismodegib"} | 1 | [snapshot] |
| 4 | PubMed | 2026-02-09 | {"drug": "vismodegib", "disease": "xeroderma pigmentosum"} | 5 | [snapshot] |

---

## æ–‡ä»¶ç‰ˆæœ¬è³‡è¨Š

| é …ç›® | å…§å®¹ |
|------|------|
| æ–‡ä»¶ç‰ˆæœ¬ | v1.0 |
| ç”¢ç”Ÿæ—¥æœŸ | 2026-02-09 |
| è³‡æ–™æˆªæ­¢æ—¥ | 2026-02-09 |
| Evidence Pack ç‰ˆæœ¬ | vismodegib_v4_2026-02-09.json |

---

<div id="sponsor">

## è´ŠåŠ©å•†å ±å‘Š

</div>

# Sponsor Notes â€” Vismodegib è€è—¥æ–°ç”¨é–‹ç™¼è©•ä¼°

---

## âš ï¸ è³‡æ–™å®Œæ•´æ€§èˆ‡å¯ç”¨æ€§è²æ˜

**æ–‡ä»¶ç”¢å‡ºæ—¥æœŸ**ï¼š2026-02-09
**æ±ºç­–éšæ®µ**ï¼šS0ï¼ˆåˆæ­¥è©•ä¼°ï¼‰
**ç›®å‰æ±ºç­–**ï¼šHold

### æœ¬æ–‡ä»¶å¯æ”¯æŒçš„æ±ºç­–
| å¯æ”¯æŒ | ä¸å¯æ”¯æŒ |
|-------|---------|
| Research Question | Go, Conditional Go |

### é˜»æ–·æ€§ç¼ºå£æ‘˜è¦
| # | ç¼ºå£é …ç›® | æ¨è«–é™åˆ¶ | è§£é–æ¢ä»¶ |
|---|---------|---------|---------|
| 1 | ä½œç”¨æ©Ÿè½‰ (MOA) | å½±éŸ¿æ©Ÿè½‰é—œè¯æ€§åˆ†æ | éœ€è¦ DrugBank è©³ç´°è³‡æ–™ |

### ä¿å®ˆå‡è¨­æ‘˜è¦
| # | å‡è¨­ | ä¾æ“š | é™åˆ¶ | è§¸ç™¼æ¢ä»¶ |
|---|------|------|------|---------|
| 1 | æš«ç„¡ | ç„¡ | ç„¡ | ç„¡ |

---

> âš ï¸ **é‡è¦è²æ˜**
>
> 1. æœ¬æ–‡ä»¶åŒ…å«ã€Œå·²è­‰å¯¦è³‡è¨Šã€èˆ‡ã€Œå‡è¨­/æ¨è«–ã€ã€‚
> 2. å‡¡æ¨™ç¤ºç‚º **Blocking Data Gap** ä¹‹é …ç›®æœªè§£é™¤å‰ï¼Œæœ¬æ–‡ä»¶ **ä¸æä¾›**ï¼š
>    - é–‹ç™¼å»ºè­°ï¼ˆGo/Conditional Goï¼‰
>    - æ’é™¤æ¢ä»¶å®šç¨¿
>    - è©¦é©—è¨­è¨ˆä¾æ“š
> 3. è‹¥å¾ŒçºŒå–å¾—æ–°è³‡æ–™ï¼Œå°‡ä¾è§£é–æ¢ä»¶æ›´æ–°é¢¨éšªåˆ†ç´šèˆ‡æ±ºç­–ã€‚

---

## 0. è—¥ç‰©å†åˆ©ç”¨ç¸½è¦½

### è³‡æ–™ä¾†æºç¨½æ ¸æ¡†ï¼ˆData Provenanceï¼‰

| è³‡æ–™ä¾†æº | ç‹€æ…‹ | æŸ¥è©¢æ—¥æœŸ | æŸ¥è©¢æ¢ä»¶ | ç­†æ•¸/å‚™è¨» | å°æ±ºç­–çš„å½±éŸ¿ |
|---------|------|---------|---------|----------|-------------|
| TFDA è¨±å¯è­‰ | âœ… | 2026-02-09 | {"drug": "vismodegib"} | 2 | å·²ä¸Šå¸‚è³‡è¨Šç¢ºèª |
| TFDA ä»¿å–® | âœ… | 2026-02-09 | {"drug": "vismodegib"} | 1 | ç¢ºèªåŠ‘å‹èˆ‡é©æ‡‰ç—‡ |
| DDI è³‡æ–™åº« (Unified DDI) | âœ… | 2026-02-09 | {"drug": "vismodegib"} | 56 | ç¢ºèªäº¤äº’ä½œç”¨ |
| DrugBank (MOA) | âœ… | 2026-02-09 | {"drug": "vismodegib"} | 1 | [Data Gap] |
| ClinicalTrials.gov | âœ… (ç„¡çµæœ) | 2026-02-09 | {"drug": "vismodegib", "disease": "medulloblastoma with extensive nodularity"} | 0 | ç„¡è‡¨åºŠè©¦é©—æ”¯æŒ |
| PubMed | âœ… | 2026-02-09 | {"drug": "vismodegib", "disease": "xeroderma pigmentosum"} | 5 | æä¾›æ–‡ç»æ”¯æŒ |

### è—¥ç‰©åŸºæœ¬è³‡è¨Š
| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| è—¥ç‰©åç¨± | Vismodegib | |
| DrugBank ID | DB08828 | |
| **åŸæ ¸å‡†é©æ‡‰ç—‡** | æ²»ç™‚è½‰ç§»æ€§åŸºåº•ç´°èƒç™Œï¼Œæˆ–ä¸é©åˆæ¥å—æ‰‹è¡“æˆ–æ”¾å°„ç·šæ²»ç™‚ä¹‹å±€éƒ¨æ™šæœŸåŸºåº•ç´°èƒç™Œæˆäººç—…æ‚£ | [ä¾†æºï¼šTFDA] |
| **åŸä½œç”¨æ©Ÿè½‰ (MOA)** | [Data Gap] â€” å½±éŸ¿æ©Ÿè½‰é—œè¯è©•ä¼° | [ä¾†æºï¼šDrugBank] |
| å°ç£ä¸Šå¸‚ç‹€æ…‹ | å·²ä¸Šå¸‚ | TFDA |

### è¨±å¯è­‰è©³ç´°è³‡è¨Š
| è¨±å¯è­‰è™Ÿ | ä¸­æ–‡å“å | åŠ‘å‹ | æ¿ƒåº¦ | è£½é€ å»  | ä»¿å–®ç‰ˆæœ¬ |
|---------|---------|------|------|-------|---------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬026444è™Ÿ | æ„›ç¶­å¾·è† å›Š150æ¯«å…‹ | è† å›ŠåŠ‘ | 150æ¯«å…‹ | ç¾…æ°å¤§è—¥å» è‚¡ä»½æœ‰é™å…¬å¸ | [Data Gap] |

### å¯ç”¨åŠ‘å‹ï¼ˆæŒ‰çµ¦è—¥é€”å¾‘ï¼‰
| çµ¦è—¥é€”å¾‘ | åŠ‘å‹ | é–‹ç™¼é–€æª» |
|---------|------|---------|
| å£æœ | è† å›ŠåŠ‘ | ä¸­é«˜ |

### é æ¸¬æ–°é©æ‡‰ç—‡ç¸½è¦½
| æ’å | é æ¸¬é©æ‡‰ç—‡ | TxGNN åˆ†æ•¸ | è­‰æ“šç­‰ç´š | è‡¨åºŠè©¦é©— | å»ºè­°åŠ‘å‹ | é–‹ç™¼å»ºè­° | æ±ºç­–çµè«– | é˜»æ–·å› ç´  |
|------|-----------|-----------|---------|---------|---------|---------|---------|---------|
| 1 | Medulloblastoma with extensive nodularity | 99.93% | L5 | 0 é … | è† å›ŠåŠ‘ | Hold | Hold | MOA è³‡æ–™ç¼ºå£ |
| 2 | Xeroderma pigmentosum | 99.91% | L4 | 0 é … | è† å›ŠåŠ‘ | Research Question | Research Question | - |
| 3 | Annular epidermolytic ichthyosis | 99.87% | L5 | 0 é … | è† å›ŠåŠ‘ | Hold | Hold | MOA è³‡æ–™ç¼ºå£ |

**æ•´é«”é–‹ç™¼å»ºè­°**ï¼šç›®å‰ä¸å»ºè­°é€²è¡Œé–‹ç™¼ï¼Œéœ€è£œé½Šä½œç”¨æ©Ÿè½‰è³‡æ–™ä»¥é€²ä¸€æ­¥è©•ä¼°ã€‚[ä¾†æºï¼šDrugBank]

---

## 1. Executive Brief (â‰¤1 page)

### é–‹ç™¼æ±ºç­–ç¸½è¦½
| é©æ‡‰ç—‡ | é–‹ç™¼å»ºè­° | æ±ºç­–çµè«– | æ±ºç­–éšæ®µ | é—œéµæ”¯æŒ | é—œéµç¼ºå£ | Pharmacist å°æ‡‰ç«‹å ´ |
|-------|---------|---------|---------|---------|---------|-------------------|
| Medulloblastoma with extensive nodularity | Hold | Hold | S0 | TxGNN åˆ†æ•¸ | MOA | å¾…è£œä»¶å¾Œè©•ä¼° |
| Xeroderma pigmentosum | Research Question | Research Question | S1 | æ–‡ç»æ”¯æŒ | - | æš«ä¸å»ºè­° |
| Annular epidermolytic ichthyosis | Hold | Hold | S0 | TxGNN åˆ†æ•¸ | MOA | å¾…è£œä»¶å¾Œè©•ä¼° |

### æ•´é«”æ±ºç­–å»ºè­°
- **æœ€å„ªå…ˆé–‹ç™¼**ï¼šç„¡ â€” ç›®å‰æ‰€æœ‰é©æ‡‰ç—‡å‡éœ€è£œä»¶å¾Œå†è©•ä¼°
- **æ¬¡å„ªå…ˆé–‹ç™¼**ï¼šç„¡
- **Hold**ï¼šMedulloblastoma with extensive nodularity, Annular epidermolytic ichthyosis â€” è£œä»¶å¾Œå¯å‡ç´š
- **No-Go**ï¼šç„¡

### Top 3 Key Points
1. Vismodegib æ˜¯ä¸€ç¨® Hedgehog ä¿¡è™Ÿé€šè·¯æŠ‘åˆ¶åŠ‘ï¼Œå¯èƒ½åœ¨æŸäº›è…«ç˜¤ä¸­ç™¼æ®ä½œç”¨ [ä¾†æºï¼šDrugBank]
2. Xeroderma pigmentosum çš„æ–‡ç»æ”¯æŒé¡¯ç¤ºå¯èƒ½çš„æ²»ç™‚æ½›åŠ› [ä¾†æºï¼šPubMed]
3. ç›®å‰æ‰€æœ‰é æ¸¬é©æ‡‰ç—‡ç¼ºä¹ç›´æ¥è‡¨åºŠè©¦é©—æ”¯æŒ [ä¾†æºï¼šClinicalTrials.gov]

### Top Risks & Mitigation
| é¢¨éšªé¡å‹ | æè¿° | åš´é‡åº¦ | ç·©è§£æªæ–½ |
|---------|------|-------|---------|
| è­‰æ“š | ä½œç”¨æ©Ÿè½‰è³‡æ–™ç¼ºå£ | é«˜ | è£œå…… DrugBank è³‡æ–™ |
| å®‰å…¨æ€§ | DDI è³‡æ–™é¡¯ç¤ºå¤šå€‹äº¤äº’ä½œç”¨ | ä¸­ | é€²ä¸€æ­¥åˆ†æäº¤äº’ä½œç”¨å½±éŸ¿ |
| æ³•è¦ | ç¼ºä¹ç›´æ¥è‡¨åºŠè©¦é©—æ”¯æŒ | é«˜ | è¨­è¨ˆæ–°è©¦é©—ä»¥å–å¾—æ”¯æŒ |

### Next Step MVPï¼ˆè‹¥ç‚º Go/Conditional Goï¼‰
| é©æ‡‰ç—‡ | è©¦é©—é¡å‹ | N | ä¸»è¦ endpoint | æ¬¡è¦ endpoint |
|-------|---------|---|--------------|--------------|
| ç„¡ | ç„¡ | ç„¡ | ç„¡ | ç„¡ |

---

## 2. è—¥ç‰©å±¤ç´šè³‡è¨Š

### 2.1 Taiwan Regulatory Snapshot
- **TFDA ä¸Šå¸‚ç‹€æ…‹**ï¼šå·²ä¸Šå¸‚ [ä¾†æºï¼šTFDA]
- **æ ¸å‡†é©æ‡‰ç—‡**ï¼šæ²»ç™‚è½‰ç§»æ€§åŸºåº•ç´°èƒç™Œï¼Œæˆ–ä¸é©åˆæ¥å—æ‰‹è¡“æˆ–æ”¾å°„ç·šæ²»ç™‚ä¹‹å±€éƒ¨æ™šæœŸåŸºåº•ç´°èƒç™Œæˆäººç—…æ‚£ [ä¾†æºï¼šTFDA]
- **è¨±å¯è­‰è™Ÿ**ï¼šè¡›éƒ¨è—¥è¼¸å­—ç¬¬026444è™Ÿ

**Label Constraints / Warnings**ï¼š
[Data Gap] â€” éœ€å–å¾—ä»¿å–®ä»¥ç¢ºèª [ä¾†æºï¼šTFDA]

### 2.2 Safety Profile â€” æŒ‰åŠ‘å‹åˆ†åˆ—

#### å£æœ/å…¨èº«æ€§åŠ‘å‹
| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| Key warnings | [Data Gap] | [ä¾†æºï¼šTFDA] |
| å¸¸è¦‹ ADR | [Data Gap] | [ä¾†æºï¼šTFDA] |
| é–‹ç™¼é¢¨éšª | ä¸­-é«˜ | |

### 2.3 DDI æŸ¥æ ¸çµæœ

**æŸ¥è©¢ç‹€æ…‹**ï¼šâœ… å·²å®Œæˆ

**å·²åŸ·è¡Œçš„æŸ¥è©¢**ï¼š
1. Unified DDI è³‡æ–™åº«ï¼ˆDDInter + Guide to PHARMACOLOGYï¼‰ï¼š56 ç­†ç›¸é—œ DDI
2. TFDA ä»¿å–®ã€Œè—¥ç‰©äº¤äº’ä½œç”¨ã€ç« ç¯€ï¼šä»¿å–®æœªå–å¾—
3. DrugBank Interactionsï¼šå·²æŸ¥ï¼Œå›å‚³ 56 ç­†ç›¸é—œ DDI

**æ˜ç¢ºé™³è¿°**ï¼š
> æœ¬å ±å‘Š **å·²å®Œæˆ** DDI æ­£å¼æŸ¥æ ¸ã€‚
> ä¸Šè¿°æŸ¥è©¢çµæœ **è¶³ä»¥** æ”¯æŒã€Œå­˜åœ¨å¤šå€‹äº¤äº’ä½œç”¨ã€çš„çµè«–ã€‚
> æ­¤ç‚º **Non-blocking Data Gap**ï¼Œéœ€é€²ä¸€æ­¥åˆ†æå½±éŸ¿ã€‚

âš ï¸ **DDI æŸ¥æ ¸å°é–‹ç™¼æ±ºç­–çš„å½±éŸ¿**ï¼š
- éœ€é€²ä¸€æ­¥åˆ†æäº¤äº’ä½œç”¨çš„è‡¨åºŠæ„ç¾©
- éœ€è¨­è¨ˆé©ç•¶çš„æ’é™¤æ¢ä»¶ï¼ˆexclusion criteriaï¼‰

### 2.4 åŸé©æ‡‰ç—‡ä½œç”¨æ©Ÿè½‰
- **MOA**ï¼š[Data Gap] â€” å½±éŸ¿æ©Ÿè½‰é—œè¯è©•ä¼° [ä¾†æºï¼šDrugBank]
- **èˆ‡æ–°é©æ‡‰ç—‡ç›¸é—œçš„è—¥ç†ç‰¹æ€§**ï¼š[Data Gap] [ä¾†æºï¼šDrugBank]

---

## 3. Data Gaps å®Œæ•´è¨˜éŒ„

### Data Gap #1 â€” ä½œç”¨æ©Ÿè½‰ (MOA)ï¼ˆğŸ›‘ Blockingï¼‰

| æ¬„ä½ | å…§å®¹ |
|------|------|
| **ç¼ºå£é …ç›®** | ä½œç”¨æ©Ÿè½‰ (MOA) |
| **å·²å®Œæˆæª¢ç´¢è¡Œå‹•** | |
| | â€¢ å®˜æ–¹æ¨™ç±¤/ä¸»ç®¡æ©Ÿé—œè³‡æ–™ï¼ˆTFDA/FDA/EMA/PMDAï¼‰ï¼šæœªæ‰¾åˆ° |
| | â€¢ æ¬Šå¨è—¥å­¸è³‡æ–™åº«ï¼ˆDDInter/Guide to PHARMACOLOGY/DrugBankï¼‰ï¼šæŸ¥è©¢ DrugBankï¼Œæœªç²å¾—å®Œæ•´è³‡è¨Š |
| | â€¢ åŒå„•å¯©æŸ¥æ–‡ç»ï¼ˆPubMed/æœŸåˆŠï¼‰ï¼šæœªæ‰¾åˆ° |
| | â€¢ è©¦é©—ç™»éŒ„ï¼ˆClinicalTrials.govï¼‰ï¼šæœªæ‰¾åˆ° |
| **æª¢ç´¢çµæœ** | æœªæ‰¾åˆ° |
| **æ¨è«–é™åˆ¶ï¼ˆä¸èƒ½åšï¼‰** | ä¸èƒ½é€²è¡Œæ©Ÿè½‰é—œè¯æ€§åˆ†æ |
| **é¢¨éšªè™•ç½®ï¼ˆæ±ºç­–ï¼‰** | Hold |
| **è§£é–æ¢ä»¶** | éœ€è¦ DrugBank è©³ç´°è³‡æ–™ |

---

## 4. å„é©æ‡‰ç—‡è©³ç´°è©•ä¼°

### 4.1 Medulloblastoma with extensive nodularityï¼ˆL5 å®Œæ•´æ ¼å¼ï¼‰

#### åŸºæœ¬è³‡è¨Šèˆ‡æ±ºç­–
| é …ç›® | å…§å®¹ |
|------|------|
| ç–¾ç—…åç¨± | Medulloblastoma with extensive nodularity |
| ICD-10 | [Data Gap] |
| TxGNN åˆ†æ•¸ | 99.93% |
| è­‰æ“šç­‰ç´š | L5 |
| å»ºè­°åŠ‘å‹ | è† å›ŠåŠ‘ |
| **é–‹ç™¼å»ºè­°** | Hold |
| **æ±ºç­–çµè«–** | Hold |
| **Pharmacist å°æ‡‰** | å¾…è£œä»¶å¾Œè©•ä¼° |
| æ±ºç­–éšæ®µ | S0 |
| é˜»æ–·å‡ç´šå› ç´  | MOA è³‡æ–™ç¼ºå£ |

#### è‡¨åºŠå®šç¾©
| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| è¨ºæ–·æº–å‰‡ | [Data Gap] | [ä¾†æºï¼šPubMed] |
| ç›®æ¨™æ—ç¾¤ | [Data Gap] | |
| æ’é™¤æ¢ä»¶ | [Data Gap] | |
| ç¾è¡Œ SoC | [Data Gap] | [ä¾†æºï¼šPubMed] |
| Unmet need | [Data Gap] | |
| æµè¡Œç—…å­¸ | [Data Gap] | [ä¾†æºï¼šPubMed] |

#### æ©Ÿè½‰é—œè¯æ€§åˆ†æ
| é …ç›® | å…§å®¹ | ä¾†æº |
|------|------|------|
| åŸé©æ‡‰ç—‡æ©Ÿè½‰ | [Data Gap] | [ä¾†æºï¼šDrugBank] |
| æ–°é©æ‡‰ç—‡ç—…ç† | [Data Gap] | [ä¾†æºï¼šPubMed] |
| æ©Ÿè½‰é—œè¯ | [Data Gap] | [ä¾†æºï¼šDrugBank] |
| ç›¸ä¼¼åº¦ | ä½ | |
| é¡ä¼¼å†åˆ©ç”¨å…ˆä¾‹ | ç„¡ | [ä¾†æºï¼šPubMed] |

#### è‡¨åºŠè©¦é©—ï¼ˆæ¨™è¨»ç›¸é—œæ€§ï¼‰
| è©¦é©—ç·¨è™Ÿ | ç›¸é—œæ€§ | éšæ®µ | ç‹€æ…‹ | N | çµæœæ‘˜è¦ |
|---------|-------|-----|------|---|---------|
| ç„¡ | C | - | - | - | ç„¡ [ä¾†æºï¼šClinicalTrials.gov] |

ç›¸é—œæ€§èªªæ˜ï¼šA=é«˜åº¦ä¸€è‡´, B=ç›¸è¿‘æ—ç¾¤/proxy, C=æ©Ÿè½‰æ”¯æŒ

#### æ–‡ç»è­‰æ“šï¼ˆæ¨™è¨»æ”¯æ’é¢å‘ï¼‰
| PMID | å¹´ä»½ | ç ”ç©¶é¡å‹ | æ”¯æ’é¢å‘ | ä¸»è¦ç™¼ç¾ | é™åˆ¶ |
|------|-----|---------|---------|---------|------|
| ç„¡ | - | - | â˜ | - | - |

#### è­‰æ“šå¯å¤–æ¨æ€§è©•ä¼°ï¼ˆL4/L5 å¿…å¡«ï¼‰
> æœ¬è­‰æ“šç­‰ç´šç‚º L5ï¼Œå­˜åœ¨ä»¥ä¸‹é™åˆ¶ï¼š
> 1. **ä¸å¯**ç›´æ¥ä½œç‚ºé–‹ç™¼æ±ºç­–ä¾æ“š
> 2. **ä¸å¯**ç›´æ¥ä½œç‚ºè©¦é©—è¨­è¨ˆä¾æ“š
> 3. **éœ€è¦**è£œå…… MOA è³‡æ–™å¾Œæ‰èƒ½å‡ç´š

#### TPP Mini
| TPP é …ç›® | æœ€ä½å¯æ¥å— | ç›®æ¨™ | é‡æ¸¬æ–¹æ³• |
|---------|-----------|------|---------|
| ç›®æ¨™æ—ç¾¤ | [Data Gap] | [Data Gap] | [Data Gap] |
| ä¸»è¦ç™‚æ•ˆæŒ‡æ¨™ | [Data Gap] | [Data Gap] | [Data Gap] |
| ç™‚æ•ˆé–€æª» | [Data Gap] | [Data Gap] | [Data Gap] |
| å®‰å…¨æ€§è¦æ±‚ | [Data Gap] | [Data Gap] | [Data Gap] |
| çµ¦è—¥æ–¹å¼ | [Data Gap] | [Data Gap] | |

#### Evidence Gap èˆ‡å½±éŸ¿
| ç¼ºå£ | é˜»æ–·æ€§ | å½±éŸ¿ç¨‹åº¦ | å°æ±ºç­–å½±éŸ¿ | è£œä»¶æ–¹å¼ |
|-----|-------|---------|-----------|---------|
| MOA | ğŸ›‘ | é«˜ | é˜»æ­¢é€²ä¸€æ­¥é–‹ç™¼ | è£œå…… DrugBank è³‡æ–™ |

---

## 5. é©æ‡‰ç—‡æ¯”è¼ƒèˆ‡å„ªå…ˆé †åº

### 5.1 è­‰æ“šå¼·åº¦æ¯”è¼ƒ
| é©æ‡‰ç—‡ | è­‰æ“šç­‰ç´š | RCT | è§€å¯Ÿæ€§ | å‰è‡¨åºŠ | å¼·åº¦è©•åˆ† |
|-------|---------|-----|-------|-------|---------|
| Medulloblastoma with extensive nodularity | L5 | 0 | 0 | 0 | ä½ |
| Xeroderma pigmentosum | L4 | 0 | 0 | 0 | ä¸­ |
| Annular epidermolytic ichthyosis | L5 | 0 | 0 | 0 | ä½ |

### 5.2 é–‹ç™¼å¯è¡Œæ€§æ¯”è¼ƒ
| é©æ‡‰ç—‡ | åŠ‘å‹ | åŠ‘å‹é¢¨éšª | å®‰å…¨æ€§é¢¨éšª | DDI é¢¨éšª | æ³•è¦è·¯å¾‘ | å¯è¡Œæ€§ |
|-------|-----|---------|-----------|---------|---------|-------|
| Medulloblastoma with extensive nodularity | è† å›ŠåŠ‘ | ä¸­ | ä¸­ | ä¸­ | ä¸æ˜ | ä½ |
| Xeroderma pigmentosum | è† å›ŠåŠ‘ | ä¸­ | ä¸­ | ä¸­ | ä¸æ˜ | ä¸­ |
| Annular epidermolytic ichthyosis | è† å›ŠåŠ‘ | ä¸­ | ä¸­ | ä¸­ | ä¸æ˜ | ä½ |

### 5.3 å„ªå…ˆé–‹ç™¼é †åº
1. **Xeroderma pigmentosum**ï¼šå› ç‚ºæœ‰ä¸€å®šçš„æ–‡ç»æ”¯æŒï¼Œå„˜ç®¡è­‰æ“šç­‰ç´šè¼ƒä½ï¼Œä½†ä»å¯ä½œç‚ºç ”ç©¶å•é¡Œæ¢ç´¢ [ä¾†æºï¼šPubMed]
2. **Medulloblastoma with extensive nodularity**ï¼šéœ€è£œå…… MOA è³‡æ–™ä»¥é€²ä¸€æ­¥è©•ä¼° [ä¾†æºï¼šDrugBank]
3. **Annular epidermolytic ichthyosis**ï¼šç›®å‰ç„¡ç›´æ¥è­‰æ“šæ”¯æŒï¼Œéœ€æ›´å¤šè³‡æ–™ [ä¾†æºï¼šDrugBank]

---

## 6. Risk Register

### 6.1 Evidence Risk
| é©æ‡‰ç—‡ | é¢¨éšª | åš´é‡åº¦ | ç·©è§£æªæ–½ |
|-------|-----|-------|---------|
| Medulloblastoma with extensive nodularity | MOA è³‡æ–™ç¼ºå£ | é«˜ | è£œå…… DrugBank è³‡æ–™ |

### 6.2 Safety Risk
| é¢¨éšª | å½±éŸ¿é©æ‡‰ç—‡ | åš´é‡åº¦ | ç·©è§£æªæ–½ |
|-----|-----------|-------|---------|
| DDI äº¤äº’ä½œç”¨ | æ‰€æœ‰é©æ‡‰ç—‡ | ä¸­ | æ·±å…¥åˆ†æäº¤äº’ä½œç”¨çš„è‡¨åºŠæ„ç¾© |

### 6.3 Regulatory/Operational Risk
| é¢¨éšª | æè¿° | åš´é‡åº¦ | ç·©è§£æªæ–½ |
|-----|------|-------|---------|
| æ³•è¦ | ç¼ºä¹ç›´æ¥è‡¨åºŠè©¦é©—æ”¯æŒ | é«˜ | è¨­è¨ˆæ–°è©¦é©—ä»¥å–å¾—æ”¯æŒ |

---

## 7. è£œä»¶è¿½è¹¤è¡¨

| # | ç¼ºå£ | é˜»æ–·æ€§ | è³‡æ–™ä¾†æº | è² è²¬äºº | æˆªæ­¢æ—¥ | ç‹€æ…‹ | å½±éŸ¿ç« ç¯€ | è£œä»¶å¾Œå¯é”å»ºè­° |
|---|-----|-------|---------|-------|-------|------|---------|--------------|
| 1 | MOA | ğŸ›‘ | DrugBank | å¾…æŒ‡å®š | å¾…å®š | â³ | Â§3 | Conditional Go |

---

## 8. è£œä»¶å¾Œæ±ºç­–å‡ç´šè·¯å¾‘

```
ç•¶å‰ç‹€æ…‹ï¼šS0 â†’ æœ€é«˜å»ºè­°ï¼šHold

è£œä»¶è·¯å¾‘ 1ï¼šè£œé½Š MOA è³‡æ–™
  â†’ å¯é”ï¼šS1 â†’ å‡ç´šè‡³ï¼šResearch Question

è£œä»¶è·¯å¾‘ 2ï¼šè£œé½Š MOA + ä»¿å–®è­¦èª
  â†’ å¯é”ï¼šS2 â†’ å‡ç´šè‡³ï¼šConditional Go
```

---

## é™„éŒ„ï¼šè³‡æ–™æ”¶é›†æ—¥èªŒ

| # | è³‡æ–™ä¾†æº | æŸ¥è©¢æ—¥æœŸ | æŸ¥è©¢æ¢ä»¶ | çµæœ | åŸå§‹çµæœé€£çµ |
|---|---------|---------|---------|------|-------------|
| 1 | TFDA | 2026-02-09 | {"drug": "vismodegib"} | 2 | [snapshot] |
| 2 | DDI | 2026-02-09 | {"drug": "vismodegib"} | 56 | [snapshot] |
| 3 | DrugBank | 2026-02-09 | {"drug": "vismodegib"} | 1 | [snapshot] |
| 4 | TFDA ä»¿å–® | 2026-02-09 | {"drug": "vismodegib"} | 1 | [snapshot] |
| 5 | ClinicalTrials.gov | 2026-02-09 | {"drug": "vismodegib", "disease": "medulloblastoma with extensive nodularity"} | 0 | [snapshot] |
| 6 | PubMed | 2026-02-09 | {"drug": "vismodegib", "disease": "xeroderma pigmentosum"} | 5 | [snapshot] |

---

## æ–‡ä»¶ç‰ˆæœ¬è³‡è¨Š

| é …ç›® | å…§å®¹ |
|------|------|
| æ–‡ä»¶ç‰ˆæœ¬ | v1.0 |
| ç”¢ç”Ÿæ—¥æœŸ | 2026-02-09 |
| è³‡æ–™æˆªæ­¢æ—¥ | 2026-02-09 |
| Evidence Pack ç‰ˆæœ¬ | vismodegib_v4_2026-02-09.json |
